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Introduction
Molecular diagnostics within cellular 
pathology have been performed since the 
late 1990s and have developed to include a 
range of techniques including short tandem 
repeat (STR) identity analysis, classiﬁ cation 
of tumours and clonality determinations in 
hematopathology. More recently, with the 
introduction of qPCR and more recently 
of next generation sequencing (NGS) as 
shown in Figure 1, precision medicine test-
ing for targeted therapies has rapidly gained 
access to daily practice and become a chal-
lenge for molecular biologists and patholo-
gists to provide the most accurate and 
relevant information. As part of this testing 
process we discuss two major challenges 
which have developed, these are:
• Firstly, pre-analytical processing of 
formalin-ﬁ xed paraﬃ  n-embedded 
(FFPE) tissue, has shown to be a criti-
cal determinant in the accuracy of 
downstream molecular testing in spe-
cialities such as mutational screening 
for targeted therapies.
• Secondly, bioinformatics has become a 
bottleneck in data processing and inter-
pretation, with the processing, analysis 
and reporting of the data shown vari-
ability between diﬀ erent laboratories.
Th is article looks to raise the awareness of 
these issues and presents possible areas for 
consideration to aid in their resolution.
Variation in pre-analytical sample 
processing of FFPE samples may 
lead to discrepancies in muta-
tional testing of actionable genes
Within cellular pathology, the majority of 
molecular diagnostic clinical sample testing 
is now carried out on FFPE samples. Gen-
erally the tissue is screened using hematox-
ylin and eosin stained sections to estimate 
the tumour content before the preparation 
process of material for subsequent molecu-
lar testing, as shown in Figure 2.
Recent studies have shown that variations 
in pre-analytical processing of samples lead 
to discrepancies in downstream molecu-
lar diagnostic testing [1–3]. Th e variations 
using singleplex mutational screening were 
largely due to the DNA extraction system 
used [2, 3], quantitation using spectropho-
tometry and training of laboratory staﬀ  as 
one study showed that pre-analytical vari-
ation was signiﬁ cant even among experi-
enced laboratories [3]. In addition both 
DNA quantitation and integrity measure-
ments play important roles in the accuracy 
of downstream multiplex testing using 
NGS.
In order to resolve some of those issues it is 
important to include control series of diag-
nostic samples, prepared according to the 
diagnostic operating procedures of the labo-
ratory with a variety of known mutations 
comprising missense mutations, simple and 
complex deletions and insertions. Assay con-
trol using known representative DNA sam-
ples from the FFPE tissue is also essential to 
ensure that the process of DNA extraction, 
quantitation and integrity measurements are 
performed correctly and consistently. Th is is 
important as DNA quality has a major eﬀ ect 
on NGS performance, i.e. poor quality DNA 
causes a higher error rate [3].
Variations in pre-analytical FFPE sample 
processing and bioinformatics: 
challenges for next generation molecular 
diagnostic testing in clinical pathology
Advances in cellular pathology techniques will improve diagnostic 
medicine. However, such improvements have to overcome many 
challenges including variations in pre-analytical sample processing, 
bioinformatics data analysis and clinical interpretation of data. In 
order to resolve such challenges, bioinformatics needs to become 
more tightly coupled to the experimental methodology development.
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Figure 1. Historical development of sequencing technology.
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In addition, diﬀ erences in quantitation meas-
urements need to be accounted for, since 
the diﬀ erent instruments used have diﬀ er-
ent ways of measuring the concentration of 
DNA. For example, variations can be seen 
between systems such as Nanodrop spectro-
photometry and Qubit ﬂ uorometry. Meas-
urement of DNA integrity is also important 
and most labs use assays such as BIOMED [4, 
5] or qPCR as the ‘gold standard’ measure.
Also European external quality assurance 
(EQA) programmes for mutation detection 
of solid tumours such as European Society 
for Pathology (ESP, www.esp-pathology.
org), European Molecular Genetics Qual-
ity Network (EMQN, www.emqn.org), and 
United Kingdom National External Qual-
ity Assessment Scheme UK NEQAS for 
Molecular Pathology (www.ukneqas.org.
uk and www.ukneqas-molgen.org.uk) may 
consider including pre-analytical (e.g. pre-
PCR) component in their assessment for 
mutation detection from FFPE samples.
Discrepancies in variant-calling 
pipelines and high-throughput 
sequencing clinical interpretation
Most diseases such as cancer and inherited dis-
eases are driven by genomic alterations. Recent 
advances in high-throughput sequencing 
technologies have enabled the identiﬁ cation 
of somatic mutations at very high resolution. 
However, accurate somatic mutation-calling 
using high-throughput sequence data remains 
one of the major challenges in genomics. For 
somatic mutation-calling, one looks for a site 
in which a variant allele exists in the tumour 
sample but not in the normal sample. Even 
with the sequence data from a normal sample, 
variant-calling in high-throughput sequencing 
data is challenging due to the multiple poten-
tial sources of errors. For example, artefacts 
occurring during PCR ampliﬁ cation or tar-
geted capture (e.g. exome-capture), machine 
sequencing errors, and incorrect local align-
ments of reads are all well documented sources 
of error [6–8]. Tumour heterogeneity and 
normal contamination contribute additional 
challenges for the tumour samples [9].
Various studies have shown low concord-
ance between diﬀ erent variant callers and 
bioinformatics analysis pipelines. Wang 
et al. [10] compared six variant callers on 
whole exome sequencing melanoma sample 
and matched blood of 18 lung tumour–nor-
mal pairs and seven lung cancer cell lines 
carried out on the Illumina HiSeq 2000. Th e 
results showed discordance between the six 
variant callers, and the top two performing 
callers could only detect 86% and 71% of 
validated mutations respectively. O’Rawe et 
al. [11] compared the analysis of ﬁ ve diﬀ er-
ent Illumina alignment and variant-calling 
pipelines on 15 exome sequencing data 
carried out using Illumina HiSeq 2000 and 
Agilent SureSelect version 2 capture kit at 
120X mean coverage. Results showed vari-
ant-calling concordance of 57.4% between 
the ﬁ ve diﬀ erent Illumina pipelines across 
all 15 exomes with the authors urging more 
caution when analysing individual genomes 
in genomic medicine. In addition, com-
parison of the two most prominent cancer 
genome sequencing databases; catalogue 
of somatic mutations in cancer (COSMIC) 
[12] and Cancer Cell Line Encyclopaedia 
(CCLE) [13] revealed marked discrepan-
cies in the detection of missense mutations 
in identical cell lines (57.4% conformity), 
where the main reason for such discrepancy 
is inadequate sequencing of GC-rich areas 
of the exome [14].
In addition to the above, various studies 
have shown discrepancies in the interpreta-
tion of genomic data between the clinician 
and diagnostic laboratory. Shashi et al. [15] 
tried to follow up the results of 93 patients 
who underwent exome sequencing. Th ey 
investigated how the clinical interpretation 
of the lab results changed the diagnosis and 
its conformity with it. Overall, the results 
showed that in 25% of patients (24/93), 
exome sequencing showed a positive result 
and in 80% (19/24) of cases, the clinicians 
agreed with the molecular diagnosis of the 
lab. However, in 20% of patients reported 
to be positive by the diagnostic lab, the cli-
nicians thought that the suggested molecu-
lar diagnosis was not correct. In addition, 
5% of patients that were considered nega-
tive by the exome lab or had a lower con-
ﬁ dence diagnosis, were eventually found 
to be positive when the exome data was 
reviewed by clinicians. In summary the 
results showed 20% false positives and 5% 
false negatives when comparing the inter-
pretation of genomic data between diﬀ er-
ent healthcare staﬀ .
However, it is worth noting that all the above 
studies used samples with high molecular 
weight DNA from cell lines, fresh frozen tis-
sue or blood and carrying out the same studies 
above using FFPE samples has the potential to 
lead to further discrepancies due to the degraded 
DNA inherent to those samples increases the 
variation at the pre-analytical steps resulting in 
downstream discrepancies in mutational proﬁ l-
ing. Th is crates it a big challenge in the devel-
opment of bioinformatics pipelines required to 
produce consistent clinically reliable data.
One way to resolve some of the bioinfor-
matics related issues is to exchange the raw 
datasets between laboratories that prefer-
entially use diﬀ erent soft ware as part of the 
soft ware validation process to establish the 
ability of the various laboratories to detect 
identical gene mutations. In addition, new 
soft ware updates need to be validated by 
analysis of prior NGS datasets covering 
simple and complex mutations. Finally, raw 
NGS datasets need to be included in EQA 
programmes as in silico assessment.
Conclusion
Although the above discussion very brieﬂ y 
surveys the current landscape in cellular 
pathology, the future of molecular diag-
nostics will undoubtedly develop to include 
integrated RNA expression analysis, DNA 
ampliﬁ cation and epigenetics. Each meth-
odology will have its own idiosyncrasies 
and will require the development of new 
clinically validated bioinformatics pipeline. 
Additionally, the need for a novel bioinfor-
matics system to support integrative analy-
sis will become essential. Although previ-
ously attempted [16], new systems need to 
be developed to support integrative high-
throughput sequencing analysis.
However, before novel bioinformatics soft ware 
solutions can be devised for big data, concerns 
about bioinformatics soft ware development need 
to be addressed. A potential starting point to 
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Figure 2. Formalin-ﬁ xed parafﬁ n-embedded (FFPE) tissue preparation for molecular pathology testing.
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address this is via supporting new bioinformatics 
courses that use soft ware engineering, computer 
programming and mathematical modelling of 
biological complexity at their core, supporting 
the education of future bioinformaticians in the 
art of bioinformatics soft ware development. Th is 
will help support a change in the current para-
digm where much of the current bespoke bio-
informatics soft ware today has been developed 
by local institutions in relative isolation, oft en in 
conjunction within the framework of a specialist 
area experimental research program [17].
Th e future landscape highly likely see the 
validation of wet chemistries (laboratory and 
clinical based) and dry (computational based) 
experiments carried out in more tightly coupled 
format than is currently performed, supporting 
clinical product development in the commer-
cial market. Also, the future will see more focus 
on the development of more eﬃ  cient adaptive 
algorithms that address the clinical questions, 
leading to faster analysis and improving the 
clarity in the interpretation of the data.
In conclusion, within cellular pathology the 
incremental development of pre-analytical 
processing from FFPE samples coupled with 
more eﬃ  cient adaptive bioinformatics algo-
rithms implementation are key areas of focus 
and crucial to the further advancement of 
next generation molecular pathology.
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POCT and preanalytics to be the themes of Labquality Days 2016
Th e Labquality Days Congress will be held at the Messukeskus Expo and Convention 
Centre in Helsinki on 11th-12th of February 2016. Labquality Days is one of the largest 
annual congresses in Scandinavia focused on quality and laboratory medicine. Th e con-
gress inspires clinical chemistry, laboratory medicine professionals, researchers, healthcare 
experts, users of point-of-care devices, medical staﬀ  working with quality issues, managers and higher level personnel administra-
tion of social- and or healthcare sectors. Th e 2016 congress themes are now announced: Point-of-Care Testing (POCT) and pre-
analytics. POCT has already a major role in healthcare workﬂ ow. Test sensitivity or speciﬁ city, price, speed and patient convenience 
are some heavily discussed topics in scientiﬁ c meetings. In preanalytics, various disciplines such as microbiology, clinical chemistry 
and hematology have their own characteristic variables. Individual analyses have some unique factors that should also be taken into 
account in order to obtain reliable results. Labquality Days will bring together leading international speakers and opinion leaders. 
Th e programme consists of scientiﬁ c lectures and panel discussions. During the congress participants have the opportunity to meet 
colleagues, share ideas and experience the vast clinical laboratory exhibition.
www.labqualitydays.com
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